MANE
Veradermics
October 8, 2026 · market open
- Rarity
- 2.31
- Peak move
- +21.23%
- Float cap
- $3.1B
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapies for prevalent dermatologic and aesthetic conditions. Its lead candidate, VDPHL01, is an oral, non-hormonal extended-release minoxidil formulation aimed at pattern hair loss, a market it serves through dermatologists and healthcare providers treating adult men and women in the United States. Earlier-stage programs target warts, alopecia areata, and molluscum contagiosum.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
1 event · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingCiti analyst Geoff Meacham maintained a Buy/High Risk rating on Veradermics with a $160 price target and opened an upside 90-day catalyst watch ahead of the Phase 3 Study 304 readout of VDPHL01 in male pattern hair loss expected in November or December 2026.